P
NBIX icon

&Partners’s Neurocrine Biosciences NBIX Stock Holding History

&Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Buy
2,187
+367
+20% +$54.4K ﹤0.01% 2011
2026
Q1 		$240K Buy
1,820
+8
+0.4% +$1.06K ﹤0.01% 2140
2025
Q4 		$257K Buy
1,812
+125
+7% +$18.1K ﹤0.01% 2008
2025
Q3 		$237K Sell
1,687
-47
-3% -$6.37K ﹤0.01% 1878
2025
Q2 		$218K Buy
+1,734
New +$199K ﹤0.01% 1793

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

&Partners's NBIX Position: Q2 2026 in Review

&Partners increased its Neurocrine Biosciences (NBIX) stake by 20% in Q2 2026, buying an estimated $54.4K and bringing the position to 2,187 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #2011.

&Partners first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • &Partners held 2,187 shares of Neurocrine Biosciences worth $369K as of Q2 2026.
  • &Partners bought 367 Neurocrine Biosciences shares in Q2 2026, an estimated $54.4K.
  • Neurocrine Biosciences made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2011 holding.
  • &Partners first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.